Welcome to our dedicated page for Inmode Ltd. news (Ticker: INMD), a resource for investors and traders seeking the latest updates and insights on Inmode Ltd. stock.
InMode Ltd. (INMD) delivers innovative radiofrequency-based solutions for minimally invasive aesthetic treatments. This news hub provides investors and medical professionals with essential updates on the company's strategic developments, technological advancements, and market leadership in medical aesthetics.
Access real-time announcements including quarterly earnings, product launch details, regulatory milestones, and partnership agreements. Our curated collection features press releases covering facial/body contouring innovations, clinical study results, and intellectual property developments central to INMD's growth strategy.
Key updates include FDA-cleared device announcements, global expansion initiatives, and R&D breakthroughs in RF energy applications. Bookmark this page for verified information on corporate governance changes, manufacturing updates, and industry conference participation directly from InMode's communications team.
InMode (NASDAQ: INMD) has announced its preliminary Q1 2025 financial expectations and upcoming earnings call details. The company anticipates Q1 2025 revenue between $77.2-$77.5 million, with a projected non-GAAP gross margin of 78-79%. InMode has also reiterated its full-year 2025 revenue guidance of $395-405 million.
The company will host its Q1 2025 earnings conference call on April 28, 2025, at 8:30 a.m. Eastern Time, featuring presentations from CEO Moshe Mizrahy, CFO Yair Malca, and CTO Dr. Michael Kreindel. The call will be accessible via various toll-free numbers and webcast through InMode's website.
InMode (Nasdaq: INMD), a leading global provider of innovative medical technologies, has announced its participation in the 24th Annual Needham Virtual Healthcare Conference. The company's leadership team, including CEO Moshe Mizrahy and CFO Yair Malca, will engage in a fireside chat on April 8, 2025, at 2:15 pm Eastern Time.
The discussion will be moderated by Michael Matson, Senior Equity Analyst. Investors can access a live webcast of the presentation, and the company will also conduct one-on-one meetings with investors during the event. Interested parties seeking to schedule meetings are advised to contact their Needham representative.
InMode (NASDAQ: INMD) has issued a comprehensive response to DOMA Perpetual Capital Management's concerns regarding capital allocation and operational management. CEO Moshe Mizrahy addressed several key points:
The company has returned approximately $500M to shareholders through share repurchases since 2022, buying back nearly 30% of company shares. InMode continues its 10% annual buyback program through 2025 and is exploring additional capital return options.
Regarding operations, InMode maintains three FDA-approved manufacturing facilities, all capable of producing their complete platform range. The company launches two new platforms/indications annually and maintains ten ongoing R&D projects. InMode has recently acquired Viveve's patent portfolio and a University of California patent for SUI.
The company has made acquisition attempts in the injectable sector but continues to seek strategic M&A opportunities that would enhance EPS. InMode emphasizes its commitment to maintaining sufficient cash reserves for future opportunities while ensuring efficient capital allocation.
InMode (Nasdaq: INMD), a leading global provider of innovative medical technologies, has announced its participation in two major investor conferences in March 2025:
- Barclays 27th Annual Global Healthcare Conference on March 12 at 9:00 am EDT in Miami, FL, featuring CFO Yair Malca in a fireside chat moderated by Senior Equity Analyst Matt Miksic
- Oppenheimer 34th Annual Healthcare MedTech & Services Conference on March 18 at 9:20 am EDT, featuring CEO Moshe Mizrahy and CFO Yair Malca in a virtual fireside chat moderated by Senior Equity Analyst Suraj Kalia
Both events will include one-on-one meetings and offer live webcasts of the presentations.
InMode (NASDAQ: INMD) reported Q4 2024 revenues of $97.9 million, down 23% from Q4 2023, and full-year 2024 revenues of $394.8 million, representing a 20% year-over-year decrease. The company's Q4 GAAP net income was $82.8 million ($1.14 per share), while non-GAAP net income was $31.1 million ($0.42 per share).
The company returned $285.4 million to shareholders through share repurchases in 2024, representing approximately 19% of share capital. The Board approved a new 10% share repurchase program, which combined with 2024 buybacks, represents about 27% of shares outstanding within a 15-month timeframe.
For 2025, InMode projects revenues between $395-405 million, with non-GAAP earnings per diluted share expected between $1.95-1.99. The company maintains a strong cash position of $596.5 million as of December 31, 2024.
InMode (Nasdaq: INMD), a leading global provider of innovative medical technologies, has announced its participation in the BTIG MedTech, Digital Health, Life Sciences & Diagnostics Tools Conference. The event will take place in Snowbird, Utah on Wednesday, February 12, 2025.
The company's Chief Financial Officer, Yair Malca, will be available for investor meetings during the conference. Interested investors can arrange meetings through their BTIG sales representatives. Additional information about the event can be accessed through InMode's investor relations website.
InMode (Nasdaq: INMD) has rescheduled its fourth quarter and full year 2024 earnings conference call to an earlier date. The call will now take place on Tuesday, February 4, 2025, at 8:30 am Eastern Standard Time, instead of the originally planned February 6. The company will release its financial results before the Nasdaq market opens on the same day.
The conference call will feature presentations from key management members, including CEO Moshe Mizrahy, CFO Yair Malca, and CTO Dr. Michael Kreindel. Participants are encouraged to pre-register through a provided link for immediate access on the call day. For those who don't pre-register, multiple dial-in options are available, including toll-free numbers for U.S. and Israel.
The call will be webcast live on InMode's website, and a replay will be available from February 4, 2025, at 12:00 p.m. Eastern Time until February 11, 2025, accessible via phone numbers or the company's website for 90 days.
DOMA Perpetual Capital Management, a major InMode (NYSE: INMD) shareholder, has sent a letter to the company's Board urging immediate action to enhance shareholder value. The letter criticizes InMode's current stock price of around $16 and highlights the company's substantial cash position of approximately $640 million with no debt.
DOMA demands a 30% tender offer in Q1 2025, followed by a 10% share buyback later in 2025. The investor estimates InMode will generate about $150 million in free cash flow in 2025. The letter also criticizes recent management decisions, including the firing of key executives and lack of production diversification outside Israel.
DOMA proposes several actions including reducing cash levels to below $100 million, establishing a small dividend program, and implementing strategic capital allocation. The investor has retained legal counsel and threatens further action if the Board fails to respond appropriately.
InMode (Nasdaq: INMD) announced it will release its Q4 and full year 2024 financial results on February 6, 2025, before the Nasdaq market opens. The company is finalizing its results, which are expected to reflect significant challenges in the aesthetics industry due to broader macroeconomic conditions.
Preliminary results indicate:
- Q4 revenue is expected between $97.0 million and $97.5 million.
- Full-year 2024 revenue is projected between $394.0 million and $394.5 million.
- Non-GAAP gross margin for the full year 2024 is expected to range from 80% to 81%.
- 2025 revenue is forecasted to be between $395 million and $405 million.
A conference call to discuss the results will be held on February 6, 2025, at 8:30 a.m. Eastern Time, featuring presentations from CEO Moshe Mizrahy, CFO Yair Malca, and CTO Dr. Michael Kreindel. Participants are encouraged to pre-register for the call to receive a unique dial-in for immediate access. The call will also be webcast live on InMode's website, with a replay available until February 13, 2025, and for 90 days on the company's website.
InMode (INMD), a leading global provider of innovative medical technologies, has announced its participation in four major investor conferences during November and December 2024. The company will be represented at the UBS Global Healthcare Conference in California, the Jefferies London Healthcare Conference in the UK, the Canaccord Genuity MedTech Forum in New York, and the Mizuho Medical Device Summit in New York.
CFO Yair Malca and CEO Moshe Mizrahy will participate in fireside chats and one-on-one meetings. Live webcasts will be available for the UBS and Jefferies conferences, scheduled for November 12 and November 20, respectively.
